Schaumburg, Ill. (PRWEB) March 18, 2014 -- Gateway for Cancer Research, a nonprofit organization funding innovative cancer clinical trials around the world, is proud to announce three outstanding finalists for the 2014 Cancer Researcher of the Year. The annual award recognizes Gateway funded cancer researchers who are positively impacting the lives of today’s cancer patients through the development of safer and more targeted cancer treatments.
In the spirit of patient-centered care, Gateway invites the public and cancer patient communities alike to participate in the voting process for this year’s Cancer Researcher of the Year recipient. Online voting for one of three finalists is open through March 31 at http://www.DemandCuresToday.org/2014voting.
This year’s finalists for Cancer Researcher of the Year include:
- Jeanne Drisko, M.D., University of Kansas Medical Center
Administering vitamin C intravenously to ovarian cancer patients suppresses cancer cell growth and reduces the side effects of chemotherapy.
- Edward Lin, M.D., Fred Hutchinson Cancer Research Center
Treating metastatic colon cancer with two drugs using an ADAPT therapy in lieu of conventional yet toxic chemotherapy improves quality of life and boosts patients’ survival.
- Mark Pegram, M.D., Stanford Cancer Institute
A new approach for treating secondary lymphedema among breast cancer patients may fundamentally change the current treatment model if proven to effectively increase limb functionality and quality of life.
Nominations were opened to cancer researchers who have received funding from the Gateway for Cancer Research. To determine the finalists, Gateway’s Awards Committee carefully reviewed each nominee’s research for true clinical innovation, compassionate care and new discoveries that improve treatment options for today’s cancer patients. On overall scientific merit and patient impact, the committee selected Drs. Drisko, Lin and Pegram as the finalists for the 2014 award.
“These researchers are making a real difference in the lives of people living with cancer today,” said Domarina Oshana, Ph.D., Director of Research & Grants at Gateway for Cancer Research. “Their contributions advance our understanding of cancer and create new treatment opportunities that can help today’s cancer patients to feel better, live longer and be cured.”
In 2013, Dr. Pierre Yves Dietrich was honored by Gateway as the first Cancer Researcher of the Year. An accomplished medical oncologist and researcher at University Hospital Geneva in Switzerland, Dr. Dietrich’s discoveries have influenced care standards for both lymphoma and brain cancer patients. Today, Dr. Dietrich is leading a Gateway-funded clinical trial to improve the prognosis of patients diagnosed with glioblastoma, one of the most prevalent and aggressive forms of brain cancer. Dr. Dietrich hopes the use of a new, robust peptide-based cancer vaccine will elicit the patient’s own immune system to identify and destroy cancer cells.
Gateway will announce this year’s recipient of the Cancer Researcher of the Year award at its Annual Meeting on April 16 in Schaumburg, Illinois. The Cancer Researcher of the Year honoree will be presented with a commemorative award, and a $30,000 grant will be given to the researcher’s institution to further his or her award-winning work. The evening event is open to the public and will include a panel discussion on the social science of cancer. Medical attendees can earn one continuing medical education (CME) credit.
Visit http://www.DemandCuresToday.org/2014voting through March 31 to view the finalists’ profiles and to cast a vote for 2014 Gateway’s Cancer Researcher of the Year. For more information and to attend Gateway’s Annual Meeting, call (847) 342-7450 or visit http://www.GatewayAnnualMeeting.org.
About Gateway for Cancer ResearchSM
Gateway for Cancer Research is a nonprofit 501 (c)(3) organization committed to funding innovative cancer research studies that can help today’s cancer patients feel better, live longer or be cured. Thanks to generous underwriting by Cancer Treatment Centers of America®, 99 cents of every dollar Gateway receives helps to fund phase I and phase II cancer clinical trials at leading research institutions all over the world. Since 1991 Gateway has supported more than 120 clinical trials and funded millions in leading-edge research, including blending the best of conventional and complementary/alternative therapies. Get involved today by visiting http://www.DemandCuresToday.org, like us on Facebook at facebook.com/demandcures and join the conversation on Twitter @DemandCures.
Adam Zuckerman, Gateway for Cancer Research, http://www.DemandCuresToday.org, +1 847.342.6704, [email protected]